Clopidogrel resistance?

Thromb Res. 2007;120(3):311-21. doi: 10.1016/j.thromres.2006.08.012. Epub 2006 Nov 14.


Clopidogrel is an effective inhibitor of platelet activation and aggregation due to its selective and irreversible blockade of the P2Y(12) receptor. Combination antiplatelet therapy with clopidogrel and aspirin is an important strategy for patients with acute coronary syndromes and those undergoing percutaneous interventions. Despite significant benefits demonstrated with combination antiplatelet treatment in large clinical trials, the occurrence of adverse ischemic events, including stent thrombosis, remains a serious clinical problem. Recent studies have demonstrated distinct response variability and nonresponsiveness to clopidogrel therapy based on ex vivo platelet function measurements. Small scale investigations have suggested that nonresponsiveness may be associated with a heightened risk for adverse clinical events. The above findings have stimulated a close examination of clopidogrel metabolism.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aspirin / therapeutic use
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / drug therapy
  • Clopidogrel
  • Drug Resistance*
  • Drug Therapy, Combination
  • Humans
  • Membrane Proteins / antagonists & inhibitors
  • Models, Biological
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / metabolism
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / metabolism
  • Ticlopidine / therapeutic use


  • Membrane Proteins
  • P2RY12 protein, human
  • Platelet Aggregation Inhibitors
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Clopidogrel
  • Ticlopidine
  • Aspirin